Skip to main content
. 2022 Nov 2;32(8):1252–1265. doi: 10.1093/hmg/ddac271

Figure 8.

Figure 8

C9orf72 and Smcr8 mitigated motor behavioral deficits in C9FTD/ALS mutant mice. (A, B) Open field assays revealed no differences in total distance traveled (A) and in time spent in the center (B) among WT, mutant and rescue group mice. (C, D) Elevated plus maze assays revealed no difference in entries into open arm (C) and in time spent in open arms (D) among WT, mutant and rescue group mice. (E) Grip strength tests showed that AAV-C9orf72 or AAV-Smcr8 significantly mitigated motor strength defects in C9TFD/ALS mutant mice. (F) Rotarod tests showed that AAV-C9orf72 or AAV-Smcr8 significantly mitigated motor strength defects in C9TFD/ALS mutant mice. Behavior tests were performed at 18–20 months. For all analyses, data are presented as mean ± SEM. N = 11–17 mice with one-way ANOVA with Bonferroni’s post hoc test (**P < 0.01, ***P < 0.001 and ****P < 0.0001).